ALPHAMAB ONCOLO.DL-000002 Market Cap ($758.75 Million)
Market Cap & Net Worth: ALPHAMAB ONCOLO.DL-000002 (3NK)
ALPHAMAB ONCOLO.DL-000002 market cap. ALPHAMAB ONCOLO.DL-000002 (F:3NK) has a market capitalization of $758.75 Million (€649.00 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #9822 globally and #1209 in its home market, demonstrating a -6.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALPHAMAB ONCOLO.DL-000002's stock price €0.67 by its total outstanding shares 968662697 (968.66 Million). Also see ALPHAMAB ONCOLO.DL-000002 (3NK) cash flow conversion for how efficiently the company converts equity into cash flow.
ALPHAMAB ONCOLO.DL-000002 Market Cap History (2019–2026)
ALPHAMAB ONCOLO.DL-000002 market cap history from 2019 to 2026. Data shows change from $1.84 Billion to $758.75 Million (-12.19% CAGR). Check 3NK share price today for real-time trading data and today's change.
ALPHAMAB ONCOLO.DL-000002 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALPHAMAB ONCOLO.DL-000002's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ALPHAMAB ONCOLO.DL-000002 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.10x
ALPHAMAB ONCOLO.DL-000002's market cap is 2.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.61 Billion | $146.02 Million | -$412.42 Million | 11.01x | N/A |
| 2022 | $1.46 Billion | $166.84 Million | -$325.72 Million | 8.76x | N/A |
| 2023 | $849.35 Million | $218.77 Million | -$210.59 Million | 3.88x | N/A |
| 2024 | $498.29 Million | $640.08 Million | $166.34 Million | 0.78x | 3.00x |
| 2025 | $1.19 Billion | $566.24 Million | -$113.94 Million | 2.10x | N/A |
Competitor Companies of 3NK by Market Capitalization
Companies near ALPHAMAB ONCOLO.DL-000002 in the global market cap rankings as of November 3, 2026. Also see ALPHAMAB ONCOLO.DL-000002 (3NK) total assets for a full breakdown of the balance sheet.
Key companies related to ALPHAMAB ONCOLO.DL-000002 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ALPHAMAB ONCOLO.DL-000002 (2019–2026)
Market capitalization of ALPHAMAB ONCOLO.DL-000002 from 2019 to today. Between 2019 and today, ALPHAMAB ONCOLO.DL-000002's market cap moved from $1.84 Billion to $ 758.75 Million, with a yearly change of -12.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €758.75 Million | -36.19% |
| 2025 | €1.19 Billion | +138.64% |
| 2024 | €498.29 Million | -41.33% |
| 2023 | €849.35 Million | -41.86% |
| 2022 | €1.46 Billion | -9.15% |
| 2021 | €1.61 Billion | -18.39% |
| 2020 | €1.97 Billion | +7.21% |
| 2019 | €1.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ALPHAMAB ONCOLO.DL-000002 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $758.75 Million USD |
| MoneyControl | $758.75 Million USD |
| MarketWatch | $758.75 Million USD |
| marketcap.company | $758.75 Million USD |
| Reuters | $758.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under th… Read more